|Articles|July 17, 2008
Galderma approved for Differin(R) Gel 0.1 percent in Japan
Lausanne, Switzerland - Galderma Pharma S.A. announced that Japan’s Health Labor and Welfare has approved Differin(R) Gel 0.1 percent (adapalene).
Advertisement
Lausanne, Switzerland
- Galderma Pharma S.A. announced that Japan’s Health Labor and Welfare has approved Differin(R) Gel 0.1 percent (adapalene).
The drug, used to treat acne vulgaris, will be marketed in Japan by Galderma KK, the Japanese arm of Galderma.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
3
Dermatology Conferences and Meetings Calendar: December 2025
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
